Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s share price was down 5.8% during mid-day trading on Wednesday . The company traded as low as $5.62 and last traded at $5.64. Approximately 66,082 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 64,025 shares. The stock had previously closed at $5.99.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings lowered shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.00.
Check Out Our Latest Analysis on GYRE
Gyre Therapeutics Price Performance
Insider Activity
In other news, CEO Ying Luo sold 10,136 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the sale, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Weiguo Ye sold 12,820 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. The trade was a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 32,535 shares of company stock valued at $219,580. 9.50% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Gyre Therapeutics
Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its position in shares of Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after buying an additional 1,900 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after buying an additional 1,941 shares during the period. JPMorgan Chase & Co. boosted its stake in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.
About Gyre Therapeutics
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
